

ANDROLOGY

www.wileyonlinelibrary.com/journal/andrology

Editors-in-Chief:

Douglas T Carrell and Manuela Simoni



Abstracts of the 10th Congress of the European Academy of Andrology

11 - 13 October 2018

Budapest, Hungary

The merged journal of the American Society of Andrology and the European Academy of Andrology, now including the former *International Journal of Andrology* and *Journal of Andrology*

WILEY



Andrology



EDITORS IN CHIEF

Douglas T. Carrell, Departments of Surgery (Urology), Obstetrics and Gynecology, and Human Genetics, University of Utah School of Medicine, UT, USA

Manuela Simoni, Unit of Endocrinology; Center of Excellence in Andrology and Sexual Medicine; Dept. of Biomedical, Metabolic and Neural Sciences; University of Modena and Reggio Emilia; Modena, Italy

ASSOCIATE EDITORS

John Amory, Seattle, WA, USA

Elisabetta Baldi, Florence, Italy

Arthur Burnett, Baltimore, MD, USA

Patricia Cuasnicú, Buenos Aires, Argentina (from 2014)

Michael Eisenberg, Palo Alto, CA

Alberto Ferlin, Padova, Italy

Aleksander Giwercman, Malmö, Sweden

Kate L. Loveland, Clayton, VIC, Australia

Rafael Oliva, Barcelona, Catalonia, Spain (from 2016)

Peter J. O'Shaughnessy, Glasgow, Scotland, UK

Andreas Meinhardt, Giessen, Germany

Ewa Rajpert-De Meyts, Copenhagen, Denmark

Paul Turek, San Francisco, CA, USA

Frank Tüttelmann, Münster, Germany

Pablo Visconti, Amherst, MA, USA

EDITORIAL BOARD

Kenneth Aston, Salt Lake City, UT, USA

Jacques Auger, Paris, France

Lars Björndahl, Stockholm, Sweden

Mona Bungum, Malmö/Lund Sweden

Livio Casarini, Modena, Italy

Kazim Chohan, Syracuse, NY, USA

Angelo Cignarelli, Bari, Italy

Don Conrad, St Louis, Missouri, USA

Gail Cornwall, Lubbock, TX, USA (AE 2012-14)

Giovanni Corona, Bologna, Italy

Martine Culty, Los Angeles, CA, USA

Carlos Da Ros, Porto Alegre, Brazil

Alan Diekman, Little Rock, AR, USA

Joel Drevet, Clermont-Ferrand, France

Erma Drobnis, Columbia, MO, USA

Waltraud Eggert-Kruse, Heidelberg, Germany

Ahmed El-Sakka, Ismailia, Egypt

Juris Erenpreis, Riga, Latvia

Sandro Esteves, Campinas, Brazil

Cristian O'Flaherty, Quebec, Canada

Luiz R. Franca, Belo Horizonte, Brazil

Elisa Giannetta, Roma, Italy

Dimitrios G. Goulis, Thessaloniki, Greece

David Handelsman, Sydney, NSW, Australia

Trine B. Haugen, Oslo, Norway

Ralf Henkel, Bellville, South Africa

William J. Huang, Taipei, Taiwan

Kathleen Hwang, Providence, RI, USA

Sabine Kliesch, Münster, Germany

Emmanuele A. Jannini, L'Aquila, Italy

Keith Jarvi, Toronto, Canada

Ates Kadioglu, Istanbul, Turkey

Csilla Krausz, Florence, Italy

Maciej Kurpisz, Poznan, Poland

Francesco Lotti, Florence, Italy

Monica Muratori, Florence, Italy

Maira O'Bryan, Melbourne, VIC, Australia

Darius Paduch, New York, NY, USA

Christopher Payne, Chicago, IL, USA

Ranjith Ramasamy, Houston, TX, USA

Rodolfo Rey, Buenos Aires, Argentina (AE 2012-14)

Vincenzo Rochira, Modena, Italy

Stefan Schlatt, Münster, Germany

Lee Smith, Edinburgh, Scotland, UK

Katja Teerds, Wageningen, The Netherlands

Jacques Tremblay, Quebec City, Canada

D.N. Rao Veeramachaneni, Fort Collins, CO, USA

Tom Walsh, Seattle, WA, USA

Joachim Wistuba, Münster, Germany

Alexander Zatsenko, Pittsburgh, PA, USA

Branko Yorn, Lubljana, Slovenia

EDITORIAL ASSISTANT

Daniele Santi

(E-mail: andrologyoffice@gmail.com)

PRODUCTION EDITOR

Carolyn Roth

(E-mail: andrology@wiley.com)

Information for Subscribers: Andrology is published in six issues per year. Institutional subscription prices for 2018 are: Print & Online: US\$1913 (US), US\$2237 (Rest of World), €1552 (Europe), £1038 (UK). Prices are exclusive of tax. Asia-Pacific GST, Canadian GST/HST and European VAT will be applied at the appropriate rates. For more information on current tax rates, please go to www.wileyonlinelibrary.com/tax-vat. The price includes online access to the current and all online back files to January 1st 2014 for International Journal of Andrology and online access to the current and all online back files for Journal of Andrology to 1980 where available. For other pricing options, including access information and terms and conditions, please visit www.wileyonlinelibrary.com/access.

Delivery Terms and Legal Title: Where the subscription price includes print issues and delivery is to the recipient's address, delivery terms are Delivered at Place (DAP); the recipient is responsible for paying any import duty or taxes. Title to all issues transfers Free of Board (FOB) our shipping point, freight prepaid. We will endeavour to fulfil claims for missing or damaged copies within six months of publication, within our reasonable discretion and subject to availability.

Back issues: Single issues from current and recent volumes of International Journal of Andrology are available at the current single issue price from cs-journals@wiley.com. Earlier issues may be obtained from Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Tel: +1 518 537 4700, Fax: +1 518 537 5899, Email: psc@periodicals.com. Single issues from current and recent volumes and fulfilment requests for the 2012 and earlier volumes of Journal of Andrology should continue to be sent to American Society of Andrology, 1100 E. Woodfield Road, Suite 520, Schaumburg IL 60173, USA info@andrologysociety.org. Access to this journal is available free online within institutions in the developing world through the HINARI initiative with the WHO. For information, visit www.healthinternetwork.org.

Publisher: Andrology is published by Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK. Tel: +44 (0) 1865 776868; Fax: +44 (0) 1865 714591. Blackwell Publishing Ltd is now part of John Wiley & Sons.

Journal Customer Services: For ordering information, claims and any enquiry concerning your journal subscription please go to www.wileycustomerhelp.com/ask or contact your nearest office: Americas: Email: cs-journals@wiley.com; Tel: +1 781 388 8598 or 1 800 835 6770 (Toll free in the USA & Canada).

Europe, Middle East and Africa: Email: cs-journals@wiley.com; Tel: +44 (0) 1865 778315

Asia Pacific: Email: cs-journals@wiley.com; Tel: +65 6511 8000

Japan: For Japanese speaking support, Email: cs-japan@wiley.com; Tel (toll-free): 005 316 50 480.

Visit our Online Customer Get-Help available in 6 languages at www.wileycustomerhelp.com.

Wiley's Corporate Citizenship initiative statement

Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, enhancing

community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts. Follow our progress at www.wiley.com/go/citizenship

ANDROLOGY (ISSN 2047-2919) is published bimonthly. US mailing agent: Mercury Media Processing, LLC, 1850 Elizabeth Avenue, Suite #C, Rahway, NJ 07065 USA. Periodical postage paid at Rahway, NJ. POSTMASTER: Send all address changes to ANDROLOGY, John Wiley & Sons Inc., C/O The Sheridan Press, PO Box 465, Hanover, PA 17331.

Copyright and Photo Copying: Andrology ©2018 American Society of Andrology and European Academy of Andrology. All rights reserved. No part of this publication (apart from articles marked 'OnlineOpen') may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising and promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissions@wiley.com

OnlineOpen: Andrology accepts articles for Open Access publication. Please visit <http://olabout.wiley.com/WileyCDA/Section/id-406241.html> for further information about OnlineOpen.

Note to NIH Grantees: Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate.

Information for Authors: Submissions for publication are online only, please consult the guidelines at [http://onlinelibrary.wiley.com/journal/10.1111/\(ISSN\)2047-2927/homepage/ForAuthors.html](http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)2047-2927/homepage/ForAuthors.html)

Disclaimer: The Publisher, the American Society of Andrology, the European Academy of Andrology and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, the American Society of Andrology, the European Academy of Andrology and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, the American Society of Andrology, the European Academy of Andrology and Editors of the products advertised.

ISSN 2047-2919 (Print)

ISSN 2047-2927 (Online)

For submission instructions, subscription and all other information visit: www.wileyonlinelibrary.com/journal/Andrology

Printed in Singapore by Markono Print Media Pte Ltd

ANDROLOGY

OCTOBER 2018 VOLUME 6 SUPPLEMENT 2

Abstracts of the 10th Congress of the
European Academy of Andrology
11 – 13 October 2018
Budapest, Hungary

Disclaimer: This abstracts book has been produced using author-supplied copy. Editing has been restricted to some corrections of spelling and style where appropriate. No responsibility is assumed for any claims, instructions, methods or drug dosages contained in the abstracts: it is recommended that these are verified independently.

WILEY

ANDROLOGY

Volume 6, Supplement 2, October 2018

Contents

- 3 Welcome
- 6 Scientific Program
- 11 Invited Lectures
- 28 Oral Communications
- 39 Posters
- 113 Author Index

WILEY

Discover this journal online at
Wiley Online Library
wileyonlinelibrary.com/journal/andrology

Italy; ²Andrology Department, Fundació Puigvert, Universitat Autònoma de Barcelona, Institut de Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Barcelona, Catalonia, Spain

Background: Hodgkin's and non-Hodgkin's lymphomas represent the most common hematological malignancies (HE) affecting men in reproductive age. Several protocols of cancer therapies have significantly improved survival rates of young patients, despite having a negative effect on testicular function, including damage or alterations to the sperm genome. The consequences of these treatments on sperm DNA represent a major concern since damage to the paternal genome may have detrimental effects on offspring. Data on post-therapy sperm DNA alterations are still controversial and limited to 2 years, thus the right timing for natural conception after treatment remains uncertain.

Objective: To evaluate the effect of cytotoxic therapies on the integrity of the sperm genome (Sperm DNA Fragmentation, SDF) after 2 (T2) and 3 years (T3) from the end of treatment in HM patients.

Methods: We analyzed the SDF of 2 HM patients groups, one evaluated 2 years post-therapy (T2 group, $n = 26$) and one evaluated 3 years post-therapy (T3 group, $n = 25$). The analysis, based on terminal-uridine nick and labelling end assay (TUNEL), was performed on 10×10^6 sperm cells. We evaluated total and brighter % SDF (SDFtot and SDFbr, respectively). The SDFbr is more strictly associated with sperm fertilizing potential and fertility outcome. Data of each group were compared with those of 58 healthy fertile men (control group) in a cross-sectional analysis.

Results: At each time points (T2 and T3) patients were divided according to the type of treatment: ABVD ($n = 11$ and 9, respectively), R-CHOP ($n = 2$ and 3, respectively) and mixed therapies (two or more different chemotherapies or chemo-radiotherapy) ($n = 13$ both for T2 and for T3). The mean %SDFtot and %SDFbr of the control group were $29.11 \pm 11.11\%$ and $19.53 \pm 9.48\%$, respectively. (i) T2 group: both %SDFtot and %SDFbr in subjects treated with ABVD ($39.06 \pm 15.08\%$, $28.54 \pm 14.28\%$) or with mixed therapies ($43.16 \pm 20.64\%$, $35.45 \pm 19.62\%$) were significantly higher than those of fertile men ($p < 0.05$, $p \leq 0.01$ and $p = 0.001$, $p < 0.001$, respectively). (ii) T3 group: no significant differences were observed at T3 between patients and controls, with the exception of % SDFtot in the group that underwent mixed therapies ($37.29 \pm 15.16\%$, $p < 0.05$). (iii) Severe DNA damage expressed as % SDFbr >75th percentile of "normality" (>25%) was observed in 55% (6/11) and 62% (8/13) of patients treated with ABVD and mixed therapies, respectively, in the T2 group. In the T3 group, SDFbr >25% was observed in 33% of patients treated with either ABVD (3/9) or R-CHOP (1/3), and in 46% (6/13) of those treated with mixed therapies.

Conclusion: Our study indicates a long-term effect of cytotoxic therapies on DNA integrity in a relatively large proportion of patients. Pathological SDF values (above the 75th percentile of fertile controls) 3 years after treatment, were observed after all type of treatment with the highest percentage in patients treated with most aggressive therapies such as combined chemotherapies or chemo-radiotherapy. DNA fragmentation analysis, particularly % SDFbr, should be proposed both to monitor the long-term

effect of cytotoxic therapies and to help in decision making on the timing of natural pregnancy.

P061

Mutations in the ADGRG2 gene as a cause of CBAVD

K. STOUFFS¹, E. EKINCI¹, V. VLOEBERGH², A. GHELDOF¹, E. DE WACHTER³, H. TOURNAYE² AND S. SENECA¹

¹Center for Medical Genetics/Research Center Reproduction and Genetics; ²Centre for Reproductive Medicine/Biology of the Testis; ³CF Clinic, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Background: Congenital Bilateral Absence of the Vas Deferens (CBAVD) is a common cause of obstructive azoospermia. Around 80% of these men have mutations in the CFTR gene. Part of the remaining 20% have a combined uro-genital problem. However, for the majority of the patients without CFTR alterations, the underlying (genetic) cause remains unknown. In 2016 Patat et al. for the first time described mutations in the X-linked ADGRG2 gene as causal of CBAVD. They analysed 26 CBAVD patients without kidney problems. In three patients, a truncating mutation was detected. Subsequently, Yang et al. (2017) described 2 more patients (out of 18) with missense mutations in the ADGRG2.

Methods: In the present study, we have investigated 20 CBAVD patients without mutations in the CFTR gene. Echography had already excluded kidney problems for the majority of these patients before their ADGRG2 gene (NM_001079858.2) was analysed by Sanger sequencing.

Results: We have identified a single patient with a truncating mutation in the ADGRG2 gene: c.920C>A, p.Ser307*. This nonsense variant has not been described before, and is located in exon 16 (from the 29 exons). Consequently, the majority of the protein (711 amino acids) is missing. Altogether, 64 patients (reported or included in our study) have been analysed for the presence of mutations in the ADGRG2 gene. PRESENTLY, around 9% of CFTR negative patients are hemizygous for an ADGRG2 gene mutation with nonsense mutations frequently seen.

Conclusion: It is worthwhile to include the analysis of the ADGRG2 gene in a routine diagnostic setting, after full investigation of the CFTR gene. Furthermore, since for a large group of patients, the underlying molecular mechanism IS STILL unknown, it is worthwhile to (re-)analyse THEM by genome-wide molecular analyses.

P062

Testosterone (T) and estradiol (E2) are poorly associated to the reduction of bone mineral density (BMD) in Young/Middle Aged Men with Human immunodeficiency virus (HIV)

S. D. VINCENTIS^{1,2}, M. C. DECAROLI^{1,2}, C. DIAZZI^{1,2}, F. MORINI¹, D. BERTANI¹, F. FANELLI^{3,4}, M. MEZZULLO^{3,4}, D. SANTI^{1,2}, U. PAGOTTO^{3,4}, G. GUARALDI⁵ AND V. ROCHIRA^{1,2}

¹Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ²Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Italy; ³Unit of Endocrinology, University of Bologna, Italy; ⁴Center for Applied Biomedical Research, University of Bologna, Italy; ⁵Multidisciplinary Metabolic Clinic, Unit of Infectious Diseases, University of Modena and Reggio Emilia, Italy

Background: Osteopenia and osteoporosis, as well as hypogonadism, are common findings in men with HIV-infection and they occur at a younger age than healthy subjects. The reduction of BMD is due to both HIV-related and HIV-unrelated factors. Previous studies suggest that T deficiency is not or poorly associated with reduced BMD in HIV context. On the other hand, estrogens are considered more important than androgens for bone health in general population, but data about their role in HIV-infected men are still scanty.

Objective: To investigate the relationship between BMD and circulating sex steroids assessed by Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) in a cohort of young/middle aged HIV-infected men.

Methods: Prospective, cross-sectional, observational study on 233 consecutive HIV-infected male patients with ongoing Highly Active Antiretroviral Therapy (HAART), attending the Multidisciplinary Metabolic Clinic of Modena. Body composition and BMD at total body, lumbar spine (L1 to L4) and total hip were measured using a Hologic QDR-2000 densitometer (DXA). LC-MS/MS was used for hormonal assays. Statistical analysis: The nonparametric Mann-Whitney *U* test was used for group comparisons because variables were not normally distributed at the Kolmogorov-Smirnov test. Correlations were performed using linear regression models.

Results: Two hundred and thirty-three HIV-infected patients were enrolled (mean age 45.29 ± 5.33 years) with average duration of HIV-infection of 190.8 ± 102.8 months. Eight patients (3.4%) had hypogonadism, defined as total T serum levels below 300 ng/dL. Considering results at DXA examination, BMD was normal in 36.5% and reduced in 63.5% (55.8% osteopenia, 7.7% osteoporosis). Both total T and E2 did not significantly differ comparing patients with normal BMD to patients with reduced BMD. Body and lumbar BMD did not show any significant difference between eugonadal patients and patients with low T and/or low E2, while both femoral BMD and femoral T-score were significantly higher in patients with E2 above 20 pg/mL than in those with E2 below 20 pg/mL ($p = 0.043$ and $p = 0.033$, respectively). At linear and stepwise multiple regression analyses, BMD was positively associated with total lean mass ($R^2 = 0.154$, $p < 0.0001$); apart from it, neither T nor E2 correlated with BMD and T-score at any site.

Conclusion: Classical factors associated to BMD as E2 and T seem to be less relevant in this model of male osteoporosis. Other specific HIV-related factors, such as changes in body composition and consequent lipodystrophy, could be more deeply involved than sex steroids as potential mechanisms in bone loss in this setting. Finally, we confirm the high prevalence of reduced BMD in young/middle aged HIV-infected men, representing one of the clinical hallmarks of the premature aging process related to HIV infection.

P063

Endogenous testosterone supports spermatogenesis even in the absence of gonadotrophins: evidence from a case report

L. ANTONIO¹, M. ALBERSEN², J. BILLEN³, G. MALEUX⁴, A.-S. V. ROMPUY⁵ AND D. VANDERSCHUEREN¹

¹Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium; ²Department of Urology, University Hospitals Leuven, Leuven, Belgium; ³Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium; ⁴Department of Radiology, University Hospitals Leuven, Leuven, Belgium; ⁵Department of Pathology, University Hospitals Leuven, Leuven, Belgium

Background: In patients with testicular dysgenesis syndrome, reduced semen quality and testicular cancer are common. We report a case of a testicular tumour in a patient with a history of cryptorchidism and oligoasthenospermia. He had an unusual hormonal profile, which was not fully explained by the pathological findings.

Case report: A 31-year-old man was referred to our tertiary care andrology unit for primary infertility with a history of bilateral orchidopexy during childhood. Testes were small (12 cc). Gynaecomastia was absent. Semen analysis repeatedly showed oligoasthenospermia (2.4–7.1 million/mL, 85–92% immotile). Gonadotrophins (LH and FSH < 0.1 U/L) were undetectable, but testosterone and estradiol were normal (850.7 ng/dL and 38.6 ng/L). Prolactin, other pituitary hormones, DHEAS, AFP, HCG and inhibin B were also normal. He denied using anabolic steroids. Suppressed gonadotrophins suggested a sex steroid producing testicular tumour. However, scrotal ultrasound only showed diffuse microcalcifications and three millimetric hypolucent lesions in the left testis, but no intratesticular mass. There were no suspicious lesions nor microcalcifications in the right testis. To further investigate the possibility of increased testicular sex steroid production, selective testicular venous sampling was performed. In the left spermatic vein, testosterone and estradiol levels were very high (3744 ng/dL and 378 ng/L), with a testis-to-periphery gradient of 4.4 and 9.0 respectively. There was no gradient in the right spermatic vein. These results confirmed increased sex steroid producing in the left testis. However, histopathological examination after orchidectomy revealed a multifocal seminoma (largest diameter 3 mm) and profuse germ cell neoplasia in situ. There were neither isolated syncytiotrophoblastic cells, nor choriocarcinoma. Leydig cell hyperplasia was present without Leydig cell tumour. HCG was remeasured with three different methods, all showing very low HCG between 0.6 and 1.1 IU/L. After orchidectomy gonadotrophin levels increased (LH 24.3 U/L, FSH 10.3 U/L), with normal total testosterone and estradiol, indicating recovery of suppression of the hypothalamic-pituitary-testis axis. Sperm concentration increased (10 million/mL.)

Conclusion: (i) Our case shows that endogenous testosterone may support spermatogenesis even without gonadotrophins. (ii) In patients with suppressed gonadotrophins, normal sex steroid levels and no testicular mass, selective testicular venous sampling can be useful in identifying the site of hormonal overproduction. (iii) Thus far, the

INDEX OF ABSTRACT AUTHORS

A					
Abad, C.	P152	Arnault, S.	OC08	Bellucci, C.	OC15
Abdelrahman, M.Y.	P108	Ashraf, C.M.	P105	Beltrame, B.	P032
Adyan, T.	P077	Ashraf, M.	P064, P135	Belva, F.	RT06-2
Agarwal, A.	P049	Aston, K.I.	L03	Bender, U.	OC05
Aglan, A.	P156	Atala, A.	OC03	Benyó, M.	P042, P073, P130
Aglietti, M.C.	OC15	Augustyniak, A.	P132	Bergmann, M.	P024
Agoulnik, A.	P104	Autilio, C.	P119	Bertani, D.	P062
Ahern, T.	P043	de Avila, P.H.B.	P154	Bertl, L.	P024
Ahmetov, D.	P150	Aydos, K.	P075, P076	Bezzi, M.	P051
Alahwany, A.S.	P141	Aydos, O.S.	P076	Bianchi, S.	P139
Alamolhoda, S.H.	P153	Ayvazova, N.	P155, P157	Biarda, B.	P132
Alary, N.	P053	de Azevedo, G.D.	P154	Billen, J.	P063
Alazzizi, H.	P141	Azzari, C.	P072	Bizzarri, M.	P025
Albersen, M.	IS03, P063			Blaauw, B.	P104
Albert, I.	P158	B		Bliatka, D.	P022
Alghobary, H.A.	P035	Babu, A.	P084	Bliznetz, E.A.	P106
Al-Hussini, M.	P108	Baert, Y.	OC04	Bobjer, J.	P010
Al-Jebari, Y.	OC01, OC02, P018	Baldi, E.	RT08-1, P016, P017, P072, P127	Boddi, V.	OC14
Allam, J.-P.	P059	Balercia, G.	L02	Bodo, M.	OC15
Almitwalli, A.	P084	Ballescà, J.L.	OC18	Bógyi, G.	P158
Almstrup, K.	L03	Bannowsky, A.	P091	Bojanac, A.K.	P066
Alnoman, A.	OC19	Baraldi, E.	P058	Bojanic, N.	P049
Álvarez, C.C.	P085	Baranov, V.	P137	Bonde, J.P.	L01cons
Ambe, A.K.	P107	Baranowska- Bosiacka, I.	P131	Bonduelle, M.	RT06-2
Amouroux, M.	P129	Barbagallo, F.	P027, P033	Borgquist, R.	P040
Ananieva- Todorova, K.	P117	Barbonetti, A.	L02, OC13, P009, P088, P110, P113, P136	Bortolanza, S.	P104
Andersson, A.-M.	P010			Breinl, E.	P151
Andreeva, M.	P074	Barnea, I.	P109	Briganti, S.	P148
Andrés Rosado Urteaga, M.	P085	Baroni, S.	P119	Britto, C.A.	P154
Antonio, L.	RT04-1, P039, P043, P063	Baroni, T.	OC15	Bronton, K.	P010
Antonouli, S.	P139	Barrachina, F.	P019	Bruno, C.	P126
Apolikhin, O.I.	RT06-1, ESAU03-4, P046	Barral, S.	RT01-2	Bryś, M.	P099
Aquila, S.	P094, P124	Bartfai, G.	RT04-3, P043	Budzinska, M.	P111, P134
Arato, I.	OC15	Bartha, É.	P083	Buelens, S.	P038
Arauz-Garofalo, G.	OC18	Bartoli, L.	P016	Bulic-Jakus, F.	P003, P066
Armani, A.	P104	Bassas, L.	P020	Buñay, J.	P006
		Bata, A.	P100	Bungum, M.	P144
		Behre, H.M.	L02, RT04-2, P007	Burgio, G.	P125
				Burkhardt, S.	OC07
				Busch, A.S.	P080
				Busetto, G.M.	P049
				Buzzetti, R.	P096

INDEX OF ABSTRACT AUTHORS

Riedl, S.	P071	Sakamoto, S.	P112	Shileiko, L.	P077
Riera-Escamilla, A.	OC06, OC16, OC17, P001, P020, P036, P060	Sala, J.L.G.	P085	Shilova, N.V.	P106
Rilcheva, V.	P117	Saleh, R.	P108	Shin, Y.S.	P002
Rocco, G.D.	P033	Salumets, A.	OC11	Shmarina, G.	P074, P077
Rochira, V.	RT04-1, P062	Salvio, G.	L02	Shtaut, M.I.	P074, P077, P106
Rodprasert, W.	P015	Sánchez, A.M.R.	P107	Shylaja, M.	P105
Rodríguez, J.M.	P085	Sanchez- Curbelo, J.R.	P020, P086	Silvestrini, A.	P126
Rogowski, J.	P099	Sandri, M.	P104	Simoni, M.	L04, OC12, P033, P058
Rohayem, J.	RT07cons	Sangeeta, K.	P034	Sincic, N.	P003, P066
Rajo, D.G.	P085	Sansone, A.	P051, P114	Sipak, O.	P131
Roli, L.	P058	Sansone, M.	P114	Sipak-Szmigiel, O.	P082
Rolland, A.D.	P053	Santi, D.	L04, OC12, P058, P062	Skakkebaek, N.E.	P015
Roman, L.D.V.	P085	Santis, M.C.D.	P058	Skosana, B.	P057
Romanelli, F.	P051, P114	Santoro, M.	P094, P124	Skouros, S.	P138
Rompuy, A.V.	P063	Sarchielli, E.	P013, P031	SŁojewski, M.	P131
Röpke, A.	OC07, P004, P079	Sari, S.	P159	SŁowikowska- Hilczer, J.J.	ESAU01-2, P043, P099
Rosado, M.	P152	Sartori, L.	P021	Sofikitis, N.	RT05-2, ESAU01-4, P087, P138
Rose, D.D.	P124	Satybaldin, D.	P128	Sola, M.	P033
Rosiak, A.	P133	Savy, N.	OC08	Soler, P.P.	P085
Rosta, G.	P151	Scavello, I.	P089, P090	Soler-Ventura, A.	OC18
Rosta, V.	P069, P098	Schileiko, L.	P074	Sorokina, T.	P074, P077
Rotter, I.	P082, P131	Schlatt, S.	L05, OC07	Spaggiari, G.	OC12, P058
Rousseaux, S.	RT01-2	Schubert, M.	OC10, P044, P080	Sperduti, S.	P033
Rozhivanov, R.	P077	Schulwitz, H.	P042, P091	Spinoit, A.-F.	P038, P071
Rudchenko, N.	P128, P150	Schuppe, H.-C.	P024, P059	Springer, A.	P071
Ruiz-Castañe, E.	OC18, P001, P020, P036, P086	Scropo, F.I.	P028	Stachowiak, E.	P132
Rusch, J.	L03, OC17	Selice, R.	P021	Stachowska, E.	P140
Ruznavszky, O.	P073	Selmi, V.	P159, P160	Ståhl, O.	OC02
RyŁ, A.	P082, P131	Sena Aydos, O.	P075	Stanic, P.	P121
Rylander, L.	OC02	Seneca, S.	P061	Starzewski, D.	P132
		Senofonte, G.	P101	Stasi, V.D.	P089
		Serafim, D.A.	P154	Stenqvist, A.	P144
		Serni, S.	OC14	Stepanova, A.	P077
		Sesti, F.	P054	Stokowy, T.	P081
		Setti, M.	P058	Stouffs, K.	P061
		Sezina, I.	P150	Strowitzki, T.	OC05
		Sforza, A.	P023, P116	Strzalkowska, A.	P132
Saad, F.	P095, P122, P123	Shaderkin, I.A.	RT06-1, P046	Suchecka, A.	P132
Sabouhi-Zarafshan, S.	OC19	Shaer, K.	P070, P146	Sungurođlu, A.	P075, P076
Sadov, S.	P015	Shaer, O.	L02, P070, P146		
Sadri-Ardekani, H.	OC03	Shaked, N.T.	P109		
Sahi, A.	P103	Shalev, A.	P109		
Saied, A.E.	P143				

S